Clinical Evidence

Publications

Peer-reviewed data and conference results on ctDNA-based MRD detection in lymphoma and solid tumors.

Peer-Reviewed Data

Published evidence for LymphoVista and CancerVista

Six peer-reviewed publications and conference presentations document the analytical performance and clinical utility of our ctDNA assays. Each citation links to the original source.

Journal Articles

Journal Article Blood 2026

MRD-2 in the GHSG HD21 trial assessed by a validated circulating tumor DNA sequencing assay

Heger et al.

View Publication

Journal Article Blood 2024; 143(6): 522–534

Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNA

Heger et al.

View Publication

Journal Article Journal of Clinical Oncology 2024

Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin Lymphoma

Heger et al.

View Publication

Journal Article Med 2021; 2(10): 1171-1194

In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection

Sobesky et al.

View Publication

Conference Abstracts

Conference Abstract Blood 2024; 144 (Supplement 1): 4355

Lymphovista HL - a Validated Assay for Genotyping and MRD Assessment in Hodgkin Lymphoma

Mattlener et al.

View Publication

Conference Abstract EHA library 05/14/24

Serial monitoring of circulating tumor DNA with an ultrasensitive assay facilitates outcome prediction in relapsed/refractory large B-cell lymphoma treated with modern agents

Schleifenbaum et al.

View Publication

For Clinical Partners

Precise Evidence. Confident Decisions.

Our clinical team answers questions on study design, endpoints, and how these data apply to your patients.

Talk to our clinical team →